China healthcare stocks were relatively weak during the first two weeks of Dec 25 as investors took profits, particularly for internet healthcare and drug innovator names. Fundamentals remain solid, supported by the new commercial insurance policy, lower costs of capital, and robust pipelines. Despite rising competition in areas like generics, GLP-1 drugs and surgical robots, companies continue to advance towards sustainable growth. Maintain OVERWEIGHT. Our top picks are BeOne Medicines, Hansoh ...
The phasing out of local car trade-in subsidies has hammered auto sales. PEV sales fell 17% yoy during the first week of December. Subsidies will resume in early-26 and trigger a sales rebound. We expect PV sales and EV sales to grow 4.9% and over 20.0% in 2026 respectively, driven by exports. Geely is catching up with BYD in terms of market share (12.1% vs 13.8%). Maintain MARKET WEIGHT. Top BUYs: CATL, Ganfeng Lithium, Minth and Geely. Top SELL: Li Auto.
Strategy | Entering Pre-Election Rally Period House dissolution is expected to still take place in late-Jan 26. Note that an earlier dissolution will not impact our positive 1H26 view. Domestic-oriented sectors tend to outperform during an election period; hence, an optimal strategy is to buy these sectors three months before election day, and then take profit one month after. Our top picks are AOT, BGRIM, CENTEL, CPALL, GLOBAL, GULF, KBANK, KTC, MINT and TFG.
Top Stories Strategy | Entering Pre-Election Rally Period House dissolution is expected to still take place in late-Jan 26. Note that an earlier dissolution will not impact our positive 1H26 view. Domestic-oriented sectors tend to outperform during an election period; hence, an optimal strategy is to buy these sectors three months before election day, and then take profit one month after. Our top picks are AOT, BGRIM, CENTEL, CPALL, GLOBAL, GULF, KBANK, KTC, MINT and TFG.
Top Stories Strategy | Small/Mid Cap Monthly -- 2025 Review; 2026 Outlook In 2025, eight names under our coverage have outperformed the HSI, which has risen 27% ytd. Our key calls JBM Healthcare, Crystal and Plover Bay have gone up 43%, 54% and 31% ytd respectively. Looking into 2026, we have two key themes: ADAS and AI plays. The names on our radar are Horizon Robotics, Karrie International and FIT Hon Teng. We also recommend to buy for quality compounders Crystal, Plover Bay, JBM Healthcare a...
Greater China Strategy | 2025 Review; 2026 Outlook In 2025, eight names under our coverage have outperformed the HSI, which has risen 27% ytd. Our key calls JBM Healthcare, Crystal and Plover Bay have gone up 43%, 54% and 31% ytd respectively. Looking into 2026, we have two key themes: ADAS and AI plays. The names on our radar are Horizon Robotics, Karrie International and FIT Hon Teng. We also recommend to buy for quality compounders Crystal, Plover Bay, JBM Healthcare and Jacobson Pharma on di...
Top Stories Company Update | Singapore Exchange (SGX SP/HOLD/S$16.70/Target: S$17.30) SGX’s 5MFY26 trading statistics outperformed our expectations on strong cash equity turnover and healthy derivative volumes. Trading activities are expected to sustain at high levels in 2HFY26, but yoy growth is likely to moderate due to a high 2HFY25 base. We like SGX’s upbeat growth outlook, with a three-year core earnings CAGR of 8.9% in FY25-28, but its current share price is close to our updated target pri...
SGX’s 5MFY26 trading statistics outperformed our expectations on strong cash equity turnover and healthy derivative volumes. Trading activities are expected to sustain at high levels in 2HFY26, but yoy growth is likely to moderate due to a high 2HFY25 base. We like SGX’s upbeat growth outlook, with a three-year core earnings CAGR of 8.9% in FY25-28, but its current share price is close to our updated target price of S$17.30 (25.5x FY27 PE, or 2SD above historical mean). Maintain HOLD.
3QFY26: More Time Required For PN17 Upliftment Highlights 9MFY26 core results deemed on track, despite E&C setbacks. Although the E&C projects in Angola and the Middle East contributed to LBITDA, the other business segments saw sequential profit improvements. The results also show a leaner balance sheet after the restructuring, with finance costs savings as per management’s guidance. We still retain our forecasts, which are pre-RED, given that 4QFY26 may likely be the earlier quarter with clea...
Top Stories Company Results | Vantris Energy (VANTNRG MK/BUY/RM0.57/Target: RM0.75) 9MFY26 core results are deemed on track despite E&C setbacks. Although the E&C projects in Angola and the Middle East contributed to LBITDA, the other segments saw sequential profit improvements. The results also show a leaner postrestructuring balance sheet. We retain our pre-RED forecasts. As long as the Brazil project continues to deliver results, our view of Vantris Energy remains unchanged. Maintain BUY and ...
Company Update | Adi Sarana Armada (ASSA IJ/BUY/Rp1,195/Target: Rp1,700) During our site visit to Bandung, we noticed consistent operational improvement and expansion across all of ASSA’s business pillars. In logistics, ASSA has deployed robotic technology in three hubs, doubling productivity, with plans to automate more hubs and build a new warehouse and cold-storage facility at its new business centre. For Caroline, the company plans to strengthen its ecosystem by partnering with repair shops ...
Company Update | Adi Sarana Armada (ASSA IJ/BUY/Rp1,195/Target: Rp1,700) During our site visit to Bandung, we noticed consistent operational improvement and expansion across all of ASSA’s business pillars. In logistics, ASSA has deployed robotic technology in three hubs, doubling productivity, with plans to automate more hubs and build a new warehouse and cold-storage facility at its new business centre. For Caroline, the company plans to strengthen its ecosystem by partnering with repair shops ...
Key Calls 2025 Review; 2026 Outlook Eight names under our coverage have outperformed the HSI ytd, which has gone up 26.8% ytd. Our key calls JBM Healthcare (2161 HK), Crystal International (2232 HK) and Plover Bay (1523 HK) have risen 43%, 54% and 31% ytd respectively. Including dividend returns, the three names have generated a ytd return of 58%, 63%, and 39% respectively. Giordano (709 HK) has underperformed the HSI (-10.2% ytd) due to business restructuring. For our HOLD calls, VSTECS Ho...
Strategy | Feedback From 1H26 Strategy Conference In Kuala Lumpur The KL roadshow focused on the 1H26 Thai equity outlook, highlighting an improving economic momentum, political stability, and strong FDI as key catalysts. Investors were positive on tourism, banking and healthcare, with high interest in politics (Mar 26 election outlook). Given the more favourable economic and financial conditions, we maintain a positive view on Thailand’s 1H26 equity outlook, with top picks including AOT, BGRIM,...
1QFY26: Seasonally Slower Start; But Growth Narrative Still Intact Highlights Below expectations (15% of ours and consensus’ expectation), Gamuda charted weaker-than-expected earnings growth of only 4% yoy. Gamuda declared a 5 sen interim dividend (1% yield; 140% payout). Maintain BUY with a higher target price of RM6.21, as we roll-over valuations to FY27. We cut our FY26 earnings forecasts by 6% to reflect delays in overseas project progress.
4QFY25: In Line; Positive Read-Through For FY26 Sales Highlights 4QFY25 results were within expectations. Net gearing improved to 0.28x on perpetual sukuk issuance. We view FY26 sales guidance of RM4b as a positive read-through, given its track record of conservative guidance at RM3b-3.5b in prior years. Maintain BUY with a target price of RM2.70, implying a PE of 15-17x supported by 20% 3-year CAGR over FY25-28.
2QFY26: Sequential Recovery Offset By Kia Malaysia Losses Highlights 2QFY26 results came in below expectations due to higher-than-expected losses from Kia Malaysia. We cut our FY26-27 forecasts by 14%/4% to factor in higher losses from Kia Malaysia. Downgrade to HOLD with a higher target price of RM0.75.
Inventory Rises Despite Lower Production Highlights MPOB’s data for Nov 25 showed a further rise in palm oil inventory levels to 2.84m tonnes despite a marginal decline in production. Maintain OVERWEIGHT on the sector premised on positive CPO price outlook in 2026 driven by both supply and demand factors. Our 2026 CPO forecast is at RM4,400/tonne. Top pick: Hap Seng Plantations (BUY, Target: RM2.65) and SD Guthrie (BUY, Target: RM6.50).
Top Stories Sector Update | Plantation MPOB’s Nov 25 data saw inventories beat market expectations despite a marginal decline in production. Maintain OVERWEIGHT on the sector. Company Results | Bermaz Auto (BAUTO MK/HOLD/RM0.70/Target: RM0.75) 2QFY26 results were below expectations, with 1HFY26 PATMI accounting for 28% and 36% of our and consensus FY26 forecasts respectively, due to higher losses from Kia Malaysia. Mazda recorded an improvement in sales volume on encouraging sales of new CBU mod...
Top Stories Strategy | Feedback From 1H26 Strategy Conference In Kuala Lumpur The KL roadshow focused on the 1H26 Thai equity outlook, highlighting an improving economic momentum, political stability, and strong FDI as key catalysts. Investors were positive on tourism, banking and healthcare, with high interest in politics (Mar 26 election outlook). Given the more favourable economic and financial conditions, we maintain a positive view on Thailand’s 1H26 equity outlook, with top picks includi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.